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Aims The Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink (OptiLink HF)
study is designed to investigate whether OptiVol ﬂuid status monitoring with an automatically generated wireless
CareAlert notiﬁcation via the CareLink Network can reduce all-cause death and cardiovascular hospitalizations in
an HF population, compared with standard clinical assessment.
Methods Patientswithnewlyimplantedorreplacementcardioverter-deﬁbrillatordeviceswithorwithoutcardiacresynchroniza-
tion therapy, who have chronic HF in New York Heart Association class II or III and a left ventricular ejection fraction
≤35%willbeeligibletoparticipate.Followingdeviceimplantation,patientsarerandomizedtoeitherOptiVolﬂuidstatus
monitoring through CareAlert notiﬁcation or regular care(OptiLink ‘on’ vs. ‘off’). The primaryendpoint is acomposite
of all-cause death or cardiovascular hospitalization. It is estimated that 1000 patients will be required to demonstrate
superiority of the intervention group to reduce the primary outcome by 30% with 80% power.
Conclusion The OptiLink HF study is designed to investigate whether early detection of congestion reduces mortality and car-
diovascular hospitalization in patients with chronic HF. The study is expected to close recruitment in September 2012
and to report ﬁrst results in May 2014.
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Introduction
In patients with advanced heart failure (HF), hospital admissions
are frequently associated with poor survival and are often
preceded by pulmonary congestion, due to pulmonary ﬂuid
accumulation.
1,2 The use of implantable cardioverter-deﬁbrillator
(ICD) and cardiac resynchronization therapy (CRT) systems has
been shown to reduce hospitalizations and mortality, and to
improve cardiac function, exercise tolerance and quality of life
(QoL) in HF patients.
3–6
Chronic HF remains a large medical and epidemiological
problem.
7 Despite signiﬁcant improvements in pharmacological
treatment, morbidity and mortality are still high,
8 and in recent
years, relatively few new approaches have proven beneﬁcial.
Device therapy, in particular ICD and the biventricular pacemaker
(generally referred to as CRT), used either alone or in combination
(CRT deﬁbrillator or CRT-D), has gained increasing acceptance
and is now implemented on a large scale. The ﬁrst ICD study,
which included patients with mild-to-moderate HF, was the
SCD-HeFT (Sudden Cardiac Death in Heart Failure) Trial;
4 it
showed that implantation of an ICD caused a 23% reduction in all-
cause mortality, the primary endpoint of the study. Previous and
current guidelines
7,9 regarding the place of ICD therapy in
chronic HF are for an important part based on this study. For
the place of CRT in HF, two other studies are of primary impor-
tance: the COMPANION (Comparison of Medical Therapy,
Pacing, and Deﬁbrillation in Heart Failure) trial
5 and the
CARE-HF (Cardiac Resynchronization-Heart Failure) trial.
10
Implantation rates of devices for HF, particularly ICD and
CRT-D, increased signiﬁcantly between 2004 and 2008 in
Europe, but there remain major differences between countries.
11
A new generation of modern ICD- and CRT-D-systems allows
the evaluation of pulmonary ﬂuid status by measuring intrathoracic
impedance. The OptiVol ﬂuid status monitoring algorithm (Med-
tronic Inc, Minneapolis, MN, USA) detects changes in thoracic
impedance resulting from accumulation of intrathoracic ﬂuid as
early signs of cardiac decompensation. Equipped with this dedi-
cated algorithm, patients are automatically and audibly alerted if
intrathoracic impedance drops below a certain threshold.
12,13
In HF patients, intrathoracic impedance measurement has been
shown as a useful tool for monitoring pulmonary ﬂuid status,
detecting HF deterioration, and predicting cardiac decompensation
before it becomes symptomatic.
14–16 When combined with
modern data-transmitting technology, information can be moni-
tored and transmitted immediately to caregivers who can then
react quickly to prevent worsening of symptoms and subsequent
hospitalization.
17,18 The CareLink Network (Medtronic Inc, Min-
neapolis, MN, USA) data-transmitting technology system is suitable
for OptiVol-generated signals. CareLink device data can either be
transmitted automatically via wireless Conexus Telemetry (Med-
tronic Inc, Minneapolis, MN, USA) or manually. Transmitted data
can either lead to the patient having an unscheduled in-ofﬁce
follow-up visit or can be used to reassure the physician that an
in-ofﬁce follow-up visit is not required.
The Optimization of Heart Failure Management using OptiVol
Fluid Status Monitoring and CareLink (OptiLink HF) study is
designed to evaluate whether the combination of OptiVol Fluid
Status Monitoring and automatically generated CareAlerts
through the CareLink Network can reduce mortality and cardio-
vascular hospitalizations. This article presents the rationale and
the design of the OptiLink HF trial.
Study design
Treatment
The OptiLink HF trial is a prospective, multi-centre, unblinded,
randomized study that aims to compare early detection of ﬂuid
overload by OptiVol monitoring linked to automatically generated
wireless CareAlert notiﬁcation of the clinician via the CareLink
Network, with standard clinical assessment. Thirty-seven German
centres with high experience in implantation and follow-up treat-
ment of ICD and CRT-D systems and 85 out-patient clinics with
access to the CareLink Network are participating in the trial.
Patients with stable chronic HF, implanted with single- or dual-
chamber ICD devices (Virtuoso, Medtronic Inc, Minneapolis, MN,
USA), or CRT systems with ICD function (CRT-D, Concerto,
Medtronic Inc, Minneapolis, MN, USA) or any subsequently
released devices that provide at least the same functionality, can
be included in the study. After inclusion, patients will be random-
ized in a 1:1 fashion between CareLink access with CareAlert in
case of OptiVol ﬂuid index threshold crossing (access arm) and
standard treatment without CareLink access and no CareAlert in
case of OptiVol ﬂuid index threshold crossing (control group).
Neither group will have any audible OptiVol patient alerts.
The OptiVol threshold can be programmed at the investigator’s
discretion to manage the balance between providing sufﬁcient
warning prior to signiﬁcant ﬂuid overload events (such as HF hospi-
talization) vs. pre-clinical events and/or premature alerts/too early
alerts. Increasing the threshold will reduce the number of alerts,
but may also delay or prevent some clinically relevant alerts. Con-
versely, reducing the threshold will increase the number of alerts,
but a larger portion may be clinically less meaningful.
Through CareLink the responsible clinician can also be alerted
about heart rhythm conditions associated with atrial tachyarrhyth-
mia (AT) and atrial ﬁbrillation (AF) (‘AT/AF alerts’). These AT/AF
alerts, intended to monitor and convey heart rate and character-
istics of AT and AF, will be programmed ‘OFF’ during the study.
Patients
Eligible patients can be of either sex, with a newly implanted or
replacement Virtuoso single-, dual-chamber ICD, or Concerto
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device. Heart failure should be New York Heart Association
(NYHA) class II or III and left ventricular ejection fraction (LVEF)
≤35%. Detailed inclusion and exclusion criteria are listed in Table 1.
The study aims to recruit 60% subjects with NYHA class III and
40% with NYHA class II.
Study endpoints
The primary endpoint of the OptiLink HF trial is the occurrence of
all-cause death or an unplanned admission to hospital for a cardi-
ovascular reason, from the day of enrolment for device implan-
tation until the 18-month follow-up visit.
Hospitalization is deﬁned as an overnight stay (or longer) in a
hospital environment or similar facility including admission to a
day care facility. Cardiovascular hospitalizations are deﬁned as hos-
pitalizations for:
† heart failure (ﬁrst or subsequent);
† acute myocardial infarction;
† unstable angina pectoris;
† symptom-driven hospitalization for cardiac arrhythmia (supra-
ventricular or ventricular arrhythmias);
† stroke or cerebral vascular accident.
Hospitalizations for elective cardiovascular procedures do not
qualify as endpoints; this includes planned admission for elective
cardioversion of AF.
Secondary endpoints of the OptiLink HF study include:
(1) all-cause mortality;
(2) heart failure-related hospitalization;
(3) cardiovascular mortality;
(4) sum of follow-up days minus days alive and out of the hospital;
(5) all-cause hospitalization during follow-up;
(6) heart failure-related hospitalization and all-cause mortality;
(7) quality of life;
(8) health economics.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
– Patients implanted with a new or replacement with Virtuoso single-, dual-chamber ICD or Concerto CRT-D or subsequently market-released
Medtronic device providing at least the same functionality
– Subjectswith CRT-Dmust fulﬁlCRT-indication(asdescribedinESCguidelinesforcardiac pacingand cardiac resynchronizationtherapy
19):EF ≤ 35%
and NYHA III, and LVEDD .55 mm, and QRS ≥ 120 ms, and optimized therapy
– Stable chronic HF NYHA class II or III for at least 30 days and LVEF ≤ 35% (most recent measurement within 6 months prior to randomization by
echocardiography or contrast ventriculography, magnetic resonance or nuclear imaging, based on local practice), on optimal target or maximal
tolerated dose of ACE-inhibitors or angiotensin receptor blockers, b-blockers and diuretics if clinically indicated to reduce ﬂuid retention and one of
the following criteria:
† at least one hospitalization due to the HF within the last 12 months before enrolment
† or one course of ambulatory intravenous diuretic treatment
† or a BNP value .400 pg/mL
† ora NT-proBNP value .450 pg/mL (in subject ,50 years), .900 pg/mL (50–75 years) and .1800 pg/mL (in subject aged .75 years) within
30 days of enrolment
Exclusion criteria
– Chronic renal failure requiring dialysis
– Serum creatinine .2.5 mg/dL, measured within 14 days prior to enrolment
– Severe COPD as determined by physician and documented in medical records (Stage III and Stage IV), suspected or conﬁrmed COPD should have a
current test of lung function (not more than 12 months before inclusion). If the ‘forced expiratory volume’ is ,1.0 L/sec, the subject may not
participate in the study
– Listing for heart transplantation or subjects with transplanted hearts
– Planned valve replacement or interventional valve therapy
– MI within the last 40 days before implantation. MI is deﬁned by typical changes in biochemical markers including troponin levels .3 times the upper
limits of normal and creatinine kinase ,2 times of upper limit, or with CKMB greater than the upper limit of normal, combined (for all enzymes) with
at least one of the following ischaemic symptoms, ECG changes consistent of diagnostic ST–T wave changes or pathological Q waves or new LBBB
– Stroke within 40 days prior to randomization
– Percutaneous coronary intervention within 3 months prior to randomization
– Cardiac surgery within 90 days of randomization
– Complex and uncorrected congenital heart disease
– Life expectancy less than 18 months in the opinion of the physician
– Situations limiting participation, not eligible to receive a CareLink monitor (e.g. hearing or speech impaired with no family member or caregiver
available to assist, or those who spend extended periods abroad, or those who intend to enrol in a study that would preclude use of the monitor)
ACE, angiotensin-converting enzyme; BNP, brain natriuretic peptide; CKMB, creatine kinase isoenzyme MB; COPD, chronic obstructive pulmonary disease; CRT(-D), cardiac
resynchronization treatment (-deﬁbrillator); ECG, electrocardiogram; EF, ejection fraction; ESC, European Society of Cardiology; HF, heart failure; ICD, implantable cardioverter
deﬁbrillator; LBBB, left bundle branch block; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP,
N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.
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Enrolment is performed 3–21 days after ICD/CRT-D device
implantation or replacement. Enrolled subjects who fail to meet
the eligibility criteria will not be randomized. If a failure to meet
eligibility the criteria is discovered after randomization, the
subject will remain in the study according to the intention-to-treat
(ITT) principle.
Subjects are randomized directly after enrolment. Randomiz-
ation is risk stratiﬁed by NYHA class II/III (40% NYHA class II/
60% NYHA class III), ischaemic/non-ischaemic cardiovascular
disease, AF and the occurrence of ventricular tachycardia (VT)/
ventricular ﬁbrillation (VF) episodes before implantation.
Subjects randomized to the access arm will be enrolled in the
CareLink Network within 25 days after implantation. In order to
ensure CareLink functionality, subjects will be trained on usage
of the CareLink monitor.
Study procedures
Clinical data are collected at baseline/enrolment, randomization,
and scheduled follow-up visits at 6 months and every 6 months
thereafter until study closure or subject death/exit. Data collection
will be performed via standard case report forms (CRFs), device
interrogation, and save-to-disk storage (control arm). In the
access arm, device interrogation and save-to-disk storage will be
replaced by data transmission to the CareLink Network.
Study centre personnel will verify the status of all cardiovascular
medications at baseline/randomization, each follow-up visit, each
telephone contact, in case of hospitalization or an adverse event
(AE) and at study exit. Recommended changes to medication
during visits, AE situations or hospitalization will be recorded on
the CRF.
The health status of subjects will be assessed using the Kansas
City Cardiomyopathy Questionnaire (KCCQ)
20 and the EQ-5D
questionnaire (standardized measure of health status developed
by the EuroQoL Group).
21 Patients will complete the question-
naires after signing the informed consent form, but before ran-
domization, and during speciﬁed follow-up visits.
Health economics
A payer perspective covering the major cost drivers of hospitaliz-
ation, emergency department visits, medication, and ‘out-patient’
visits will be used. Healthcare utilization based on emergency
department visits, hospitalizations, out-patient visits, and all
further utilization of healthcare resources will be collected based
on discharge summaries (if applicable) and CRF-based information.
Utilization of medication will be based on information recorded on
the CRF at follow-up visits or during any other patient contacts.
Life expectancy will be derived from mortality data collected
within the trial.
Follow-up
During follow-up, patients are monitored by personal visits to the
clinic and via other contacts. Follow-up is required at 6 months,
and then every 6 months post-randomization, until study closure,
or subject exit due to death or other causes. The follow-up sche-
dule is shown in Figure 1. During these follow-up visits,
interrogation of the device allows monitoring of the condition of
the therapy system and of the patient’s clinical status. In addition,
QoL questionnaires (KCCQ and EQ-5D) are collected at the
6-month routine follow-up visit and at the 18-month routine
follow-up/study exit visit.
Any interim/additional contacts with the patient are at the dis-
cretion of the individual centre and may include follow-up both
for technical ICD/CRT-D device testing and/or for HF manage-
ment. Additional data will be collected during unscheduled ofﬁce
visits, emergency department visits, hospitalizations, data associ-
ated with an intervention algorithm, telephone contacts, system
modiﬁcations, AEs, study deviations and study exit/death.
In order to assure a reliable function of data transmission via
CareLink for subjects in the access arm, study personnel are
strongly advised to use the calendar on the CareLink clinician
website to schedule automatically transferred CareLink trans-
missions through Conexus.
Adverse events and hospitalizations
All new and/or worsening AE information will be collected from
the time of enrolment until the event is resolved or the study
ends. All AEs regardless of relatedness or outcome must be
reported. This includes a description of the event, the diagnosis,
the date of event onset, the relationship of the event to any pro-
cedure or to the device system, the outcome of the event, and the
date on which the event was ﬁrst noticed by the investigator.
Additionally, actions that were taken as a result of the event
have to be documented.
The Medical Dictionary for Regulatory Activities (MedDRA)
will be used to assign a key term for each event based on the
information provided by the investigator. The key term will be
reviewed and adjudicated by an independent event committee
(see Appendix). The event committee will also regularly assess,
review and classify all AEs including hospitalizations, emergency
department visits, urgent and non-urgent unscheduled ofﬁce
visits. Additionally, the event committee will review and classify
device-detected sustained VT/VF episodes to determine which
episodes were appropriately detected sustained VT/VF episodes
for the safety composite event deﬁnition.
Healthcare utilization will be measured by data received from
the completion of an Adverse Event Form or CareAlert Evaluation
Form in case of hospitalizations or an Emergency Department visit.
Crossover and patient withdrawal
Study participants are required to remain in the randomized arm
to which they are assigned. Crossover is prohibited unless
deemed clinically necessary by the investigator and approved by
a designated member of the OptiLink HF Executive Committee
who will review the rationale for crossovers. In order to achieve
approval the investigator must inform the sponsor upfront about
intended crossover. An approved crossover is deﬁned as any
instance when the study centre personnel makes a permanent,
deliberate, medically intended decision to use Cardiac Compass
Trends and/or HF-Management Report to optimize patient care
in the control arm.
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completion regardless of the reason will be considered as an
early withdrawal.
Device programming and system
modiﬁcation
Device programming and programming of the level of CareLink-
based data transmission are at the centre’s own discretion.
In the event of a system modiﬁcation, such as removal of a study
device without replacement with a single- or dual-chamber Vir-
tuoso ICD system or Concerto CRT-D or successor models, sub-
jects initially randomized to the access arm will be crossed-over to
the control arm, but analysed in the access arm (ITT principle).
Intervention algorithm
An intervention algorithm will be performed and documented if:
† CareAlert due to OptiVol ﬂuid index exceeding the OptiVol
threshold (access arm only);
† new or worsening signs and/or symptoms of cardiovascular
decompensation appear (access and control arm).
The detailed intervention algorithm is shown in Figure 2.
Study exit
A study exit will be documented for any of the following: subject
death, study closure, subject withdrawal, investigator withdrawal,
or subject lost to follow-up.
Ethical conduct and data management
The OptiLink HF study is registered on www.clinicaltrials.gov with
the registration number NCT00769457. The study will be con-
ducted in compliance with ISO-14155, guided by Good Clinical
Practice and in accordance with the Declaration of Helsinki and
the laws and regulations of the Federal Republic of Germany. All
centres must provide written approval from the local Medical
Ethics Committee. All patients will be required to provide
written informed consent to participate in the study.
OptiLink HF is sponsored by Medtronic Inc. (Minneapolis, MN,
USA). The sponsor is responsible for training of personnel
involved into the study. All devices are market released and are
used according to licensed indications. Study data management is
performed by the Contract Research Organization Pierrel
Research GmbH Essen, Germany.
Statistical analysis
The OptiLink HF trial is designed to show the superiority of
OptiVol ﬂuid status monitoring with automatically generated
Figure 1 Schedule of follow-up in the access arm (with remote monitoring and follow-up) and in the control arm (with in-ofﬁce visits only).
SAEs, serious adverse events.
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Network, compared with standard clinical assessment. This
should be reﬂected by a relevant decrease in the rate of all-cause
death or cardiovascular related hospitalization during the follow-up
period.
The following hypothesis will be investigated:
H0 : Scontrol = Saccessvs.H1 : Scontrol = Saccess
with Scontrol and Saccess denoting the survival functions for freedom
from all-cause death or unplanned cardiovascular-related hospital-
ization within 18 months for the control arm and access arms,
respectively. Group comparison will be performed on a-level of
5% using a two-sided log-rank test. The ITT population will be
used for the primary analysis.
The study is sized to have 80% power to detect a 30% reduction
in the percentage of patients who experience a primary event in
the ﬁrst 18 months after randomization. For sample size calcu-
lation, the following assumptions are made: type I error a ¼
0.05, control arm proportion event-free at 18 months of 72.0%,
difference between treatment arms of 30%, which means an
8.4% absolute risk reduction; access arm proportion event-free
at 18 months of 80.4%, all subjects are followed for 1.5 years.
Based on these assumptions, the total sample size of 798 sub-
jects will have 80% power to detect a difference between the
rates of all-cause death or cardiovascular-related hospitalization
in the two treatment arms. This is based on the method from
Lakatos
22 and Cantor,
23 setting accrual time to 0 to model
subject exit after 18 months (SAS Power and Sample Size
module, version 3.1). Taking into account early study termination
and treatment non-compliance including cross-over, 1000 subjects
will be enrolled in the study.
Missing values for the primary endpoint will be avoided to the
extent possible. Patients for whom the randomized treatment is
discontinued will be followed continuously. The ITT analysis will
include these patients in the arm to which they were randomized.
In case of study exit, attempts will be made to obtain at least vital
status and dates of unplanned cardiovascular hospitalizations. Any
remaining missing values will be taken into account in the primary
analysis by censoring the patient at the last available visit.
Two interim analyses are planned when 33 and 67% of the 238
expected primary endpoints have been accrued. At the interim
analyses, the primary endpoint and the secondary mortality end-
point will be analysed. The Data Safety Monitoring Board
(DSMB) will review the results and will advise the Study Executive
Committee about continuation of the study. The DSMB will con-
sider stopping for success if the primary endpoint occurs signiﬁ-
cantly more often in the control arm with P , 0.0001 for the
ﬁrst and P , 0.001 for the second interim analysis. However, it
will consider stopping for harm if the primary endpoint occurs sig-
niﬁcantly more often in the access arm with P , 0.01 or if mor-
tality is signiﬁcantly higher in the access arm with P , 0.05. The
ﬁnal analysis will use a modiﬁed alpha to compensate for the
interim analyses, maintaining total type I error at 0.05.
All secondary variables will be analysed by descriptive statistical
methods. For discrete variables, frequencies and percentages will
be determined, for continuous variables parameters for location
and dispersion will be calculated. Shift-tables and pre–post differ-
ences can be determined, if applicable.
Subgroup analyses will be carried out for the presence of ischae-
mic and non-ischaemic cardiovascular disease, subjects with or
Figure 2 Intervention algorithm.
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implantation (primary vs. secondary prevention).
Timelines
The ﬁrst OptiLink HF patient was enrolled in September 2008. At
the time of manuscript submission, almost 500 patients have been
included in the study and study recruitment is expected to be com-
pleted in September 2012. Thus, the last subject visit should occur
by the end of March 2014 and the ﬁrst results on the primary
objective should be available by the end of 2014.
Discussion
The OptiLink HF trial is designed to evaluate whether OptiVol
ﬂuid status monitoring with an automatically generated wireless
CareAlert notiﬁcation via the CareLink Network reduces all-cause
death and cardiovascular hospitalizations in a HF population, com-
pared with standard clinical assessment.
Modern and device associated HF disease management uses,
besides CRT, two new strategies. The ﬁrst new strategy involves
the measurement and continuous monitoring of intrathoracic
impedance as a surrogate parameter of changes in pulmonary
ﬂuid status. Preliminary data showed that the OptiVol algorithm
for intrathoracic impedance measurement allowed the detection
of clinical HF with a sensitivity of 60% and a positive predictive
value of 60% in 373 patients over a follow-up period of 4.2
months.
15 These data were conﬁrmed by Ypenburg et al.,
14 who
reported a sensitivity of 60% and a speciﬁcity of 73% for the assess-
ment of HF, depending on the selected threshold for the OptiVol
alert, in 115 patients over a follow-up period of 9+5 months.
Ongoing trials are currently trying to evaluate the sensitivity of
the ﬂuid detection algorithm for predicting HF-related hospitaliz-
ations,
24 and to investigate whether the clinical outcome of
patients with an implanted HF device can be improved by using
information from intrathoracic impedance monitoring.
25
However, none of these trials are designed to analyse whether
ﬂuid status monitoring reduces all-cause death and cardiovascular
hospitalizations in HF patients as the OptiLink HF trial does.
The second new strategy is the use of telemonitoring for device-
based data transmission. The TEN-HMS (Trans-European
Network-Home-care Management System) trial was one of the
ﬁrst to show that mean duration of hospital admissions was
reduced by 6 days and mortality was reduced signiﬁcantly with
home telemonitoring as compared with usual care in 426 HF
patients.
26 However, although TEN-HMS measured weight,
blood pressure, heart rate, and rhythm, it was not capable of
measuring implantable device-based parameters. Using CareLink
for the ﬁrst time in 67 patients, remote monitoring was seen as
a potential tool to improve the clinical management of patients
with CRT-D devices.
17 Especially in HF patients, CareLink was
shown to reduce in hospital visits in 70% of patients with intrathor-
acic impedance alerts.
18
Remote patient management by direct transmission of data
related to patient’s health status is a promising strategy for improv-
ing HF outcomes. The efﬁcacy of telemonitoring using a telephone-
based interactive voice-response system that collects daily infor-
mation regarding symptoms and weight was recently tested in a
large-cohort multi-centre clinical trial conducted by Chaudhry
et al.
27 Although patients randomized to the intervention group
reported their general health- and HF-related symptoms on a
daily basis, the investigators did not observe a correlation
between the reduction in hospital re-admission or death risk and
the use of telemonitoring when compared with usual care.
The Telemedical Interventional Monitoring in Heart Failure
(TIM-HF) study uses a remote monitoring system with the ability
to monitor the electrocardiogram, blood pressure, and body
weight of the patient via a mobile phone network connection. Tel-
emedical Interventional Monitoring in Heart Failure aims to assess
total mortality compared with standard health-care patients, and
has already recruited 710 stable chronic HF patients. It is expected
that TIM-HF will provide important data on the impact of teleme-
dical management.
28 However, OptiLink HF is the ﬁrst trial to use
CareAlert notiﬁcation via the CareLink Network for ﬂuid status
monitoring to assess all-cause death and cardiovascular hospitaliz-
ations in HF patients.
The occurrence of ventricular but also atrial arrhythmias is a
strong predictor of outcome in patients with CRT. New onset AF
is especially detrimental to CRT patients. Buck et al.
29 showed
that failure of CRT was associated with new-onset AF. They
studied 114 CRT patients with (49%) or without (51%) known
AF, and used total atrial conduction time measurements to predict
CRT response. They also found that the response rate was signiﬁ-
cantly higher when an improvement of one or more NYHA class
was found during CRT. This is in accordance with other reports
showing that the prevalence of AF increases with an increase in
NYHA class.
30 Although the use of arrhythmia alerts would be
helpful to guide therapy, participating study centres are not
allowed to individually programme AT/AF alerts in OptiLink HF.
Two other aspects of the OptiLink HF study have not been pre-
viously addressed by any other study. One is the close collabor-
ation and networking between the implanting hospitals and the
out-patient clinics, based on the CareLink Network system. This
allows remote patient and device management by the implanting
centre using the CareLink data, for example, in case of problems
regarding rhythm therapy programming, during patient visits to
the out-patient clinic. Another aspect is that the use of the Care-
Link Network system might have an impact on health economics,
the extent of which is unknown at present.
In summary, the OptiLink HF trial is designed to investigate
whether OptiVol ﬂuid status monitoring with an automatically gen-
erated wireless CareAlert notiﬁcation using the CareLink Network
can reduce all cause death and cardiovascular hospitalizations in
HF patients implanted with ICD or CRT-D systems.
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Appendix
Study Committees
Executive Board: The Executive Board consists of eight physicians and
one member of the sponsor study team. Members: M. Bo ¨hm, J. Brach-
mann, K. Rybak, G. Klein, R. Bosch, C. Butter, H-P. Schultheiss, E.
Erdmann.
Event Adjudication Committee (EAC)
The Event Adjudication Committee consisting of three independent
physicians will adjudicate events for study objectives and document
event classiﬁcations. Members: M. Haass, W. Haverkamp, S. Stoerk.
The event committee members do not otherwise participate in the
study (i.e. no study centre investigator is involved) to assure that the
transmission of information to the study centre investigators about
events triggering per study arm or per subject does not take place.
Medtronic personnel may facilitate the EAC meeting (e.g. statistician,
clinical trial leader), but they will not be voting members. The EAC
will not be made aware of the randomization assignment of study
subjects.
Data Safety Monitoring Board (DSMB)
An independent Data Safety Monitoring Board is established to review
the interim data analyses as well as to periodically review the total inci-
dence of AEs and deaths in this study. The DSMB for this study consists
of members with study related backgrounds. Members: S. Anker, K.
Swedberg, H. Wellens, L. Tavazzi, S. Pocock.
Up to two additional investigators participating in this study may
take part in the open meetings to offer clariﬁcation of events, but
will not be given voting privileges. Medtronic personnel may facilitate
the DSMB meeting (e.g. clinical trial leader, statistician), but they will
not be voting members.
A quorum of the committee will review the results of each interim
analysis in which the results are analyzed against the primary objective.
A summary of AEs will also be reviewed at this time. Review and con-
sensus by the entire committee is required to recommend that the
study should be stopped. All documentation will be anonymized in
terms of clinical centre and subject identiﬁers.
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